As of September 30, 2025, the Company reported cash and cash equivalents of $13.7 million compared to $22.8 million as of December 31, 2024. The Company believes its cash and cash equivalents as of September 30, 2025, will be sufficient to meet its currently projected operating expenses and capital expenditure requirements into the fourth quarter of 2026.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APRE:
- Aprea Therapeutics Advances ATRN-119 Study for Solid Tumors
- Aprea Therapeutics Advances with Phase 1 Study of APR-1051 in Solid Tumors
- Aprea Therapeutics Reports Promising Trial Results for APR-1051
- Aprea Therapeutics provides update from ACESOT-1051 t rial
- Aprea Therapeutics: Strategic Advancements and Unique Positioning Drive Buy Recommendation